[Page Banner Image]

The following is a review of developments affecting health care in Canada

The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.

The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.

[HRule Image]

Healthcare in Canada - April 1999

Ontario energy, science and technology minister, Jim Wilson has announced a funding consortium of $90.5 million to fund seven new projects in biotechnology, drug discovery, telecommunications, microsatellites, laser micromachining and financial research. The provincial government, through the Ontario Research and Development Challenge Fund (ORDCF), will invest $29.2 million, the University of Toronto is contributing $30.2 million and corporate sponsors will provide $31.1 million. Some of the projects to receive funding include: With project partners Astra Pharma and the University of Toronto, the $7 million Drug Discovery and Biotechnology project will investigate new drugs for debilitating diseases including Parkinson's and Alzheimer's. GlycoDesign, Apotex and the University of Toronto will receive $1.5 million to develop new pharmaceuticals to fight viral and bacterial diseases ranging from the common cold to meningitis.

LYMErix, a vaccine to prevent lyme disease (Recombinant OspA), manufactured by SmithKline Beecham Biologicals, is now available in Canada. LYMErix has been proven effective in the prevention of both definite Lyme disease (characteristic symptoms with serologic diagnosis) and asymptomatic infection (no symptoms, but serologic diagnosis of infection). Lyme disease, an emerging infectious disease, is a potentially serious multi-stage bacterial infection with a wide range of symptoms -- from a characteristic skin rash and flu-like symptoms to arthritis and heart abnormalities. In Canada, Lyme disease is considered endemic in parts of B.C. and in southwestern Ontario -- near Long Point and Point Pelee. However, in addition to these endemic areas, the ticks that are known to transmit Lyme disease have been found in over 250 locations across Canada, including Quebec, northern Ontario, parts of the Prairies and the Atlantic regions.

LYMErix is a genetically engineered vaccine that contains lipoprotein OspA, an outer surface protein of the causative Lyme disease bacterium, Borrelia burgdorferi.

[HRule Image]

* Healthcare in Canada - March 1999
* Healthcare in Canada - Febuary 1999
* Healthcare in Canada - January 1999
* Healthcare in Canada - December 1998
* Healthcare in Canada - November 1998
* Healthcare in Canada - October 1998
* Healthcare in Canada - September 1998
* Healthcare in Canada - August 1998
* Healthcare in Canada - July 1998
* Healthcare in Canada - June 1998
* Healthcare in Canada - May 1998
* Healthcare in Canada - April 1998
* Healthcare in Canada - March 1998
* Healthcare in Canada - February 1998
* Healthcare in Canada - January 1998
* Healthcare in Canada - July 1997
* Healthcare in Canada - June 1997
* Healthcare in Canada - May 1997
* Healthcare in Canada - April 1997
* Healthcare in Canada - March 1997
* Healthcare in Canada - February 1997
* Healthcare in Canada - January 1997
* Healthcare in Canada - December 1996
* Healthcare in Canada - November 1996
* Healthcare in Canada - October 1996
* Healthcare in Canada - September 1996
* Healthcare in Canada - August 1996
* Healthcare in Canada - July 1996
* Healthcare in Canada - June 1996

[HRule Image]

HomePage | Company Profile | Services | Research Reports Available
Product Developments Worldwide | Research News | Links

[HRule Image]
Send mail to stratcom@pagebleu.com with questions or comments about this web site.

Concept and Design Blue Page Productions
Copyright © 1996-1999 STRATCOM

Last modified: May 3, 1999